Diabetes · SGLT2 Inhibitor and BiguanideRegulatory Approvalcommercialmid-term

Aurobindo Pharma submits ANDA for Empagliflozin and Metformin Hydrochloride

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Aurobindo Pharma2 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/19/2026, 6:32:33 PM

Assessment confidence: 69% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Aurobindo Pharma's submission of an ANDA for Empagliflozin and Metformin Hydrochloride signifies a new competitive entrant in the diabetes market. This could disrupt pricing and market share dynamics for established players in the SGLT2 and biguanide segments, necessitating strategic adjustments. Regulatory context from FDA (FDA TA — EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 21 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Aurobindo's entry on market dynamics and pricing strategies for diabetes treatments. The strongest clinical anchor is Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (ClinicalTrials.gov), moderate corpus alignment. In Diabetes · SGLT2 Inhibitor and Biguanide, 8 regulatory and 2 competitive items passed relevance filtering for Aurobindo Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need.

Regulatory Outlook

Regulatory risk is concentrated around FDA TA — EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (ORIG) (FDA). Entity match (aurobindo pharma); Regulatory pathway relevance (nda). The FDA's review process will determine the approval timeline, which could influence market entry strategies for competitors.

Key Risks

Elevated medium regulatory exposure for Aurobindo Pharma could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age) could weigh on Aurobindo Pharma through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The entry of Aurobindo could lead to increased price competition, potentially impacting revenue and market share for existing diabetes treatments.
Portfolio teams should assess the impact of Aurobindo's entry on market dynamics and pricing strategies for diabetes treatments.

What Would Change This Assessment

This becomes more urgent if Monitor the FDA's review timeline and any subsequent approvals or market entries by competitors.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA TA — EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (aurobindo pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (metformin hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (metformin hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (metformin hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (metformin hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (metformin hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (metformin hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (metformin hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Anti-inflammatory Dietary Intervention in Patients With Type 2 Diabetes: A Randomized Controlled Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Assessment of the Efficacy of Highly Standardized Ginger and Perilla Nutraceutical (Dispepril®) in Improving Gastric and Intestinal Symptoms in Patients With Functional Dyspepsia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Aut
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Pancreas Lipotoxicity in T2D: Edinburgh Diabetes Remission Study (EDRS)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Dulce Digital 2.0 - Innovative Diabetes Self-Management in the Digital Age
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source

Discovery of azaindole/indole-fused pyrimidine tetracyclic scaffolds as novel potent CDK7 inhibitors.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Self-perceived learning outcomes of academic detailing discussing rational therapy with proton pump inhibitors among general practitioners in Norway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of caffeine gum on same-day and subsequent neuromuscular performance under a standardized resistance-priming condition in male basketball players.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Aurobindo Pharma
Empagliflozin
Metformin Hydrochloride
Biguanides

Commercial impact

medium

The entry of Aurobindo could lead to increased price competition, potentially impacting revenue and market share for existing diabetes treatments.

Regulatory impact

medium

The FDA's review process will determine the approval timeline, which could influence market entry strategies for competitors.

What to watch

Monitor the FDA's review timeline and any subsequent approvals or market entries by competitors.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.